title: Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study.
abstract: BACKGROUND
  Statins may have anti-inflammatory and immunomodulatory effects that could reduce the risk of mortality from influenza virus infections.
  
  
  METHODS
  The Centers for Disease Control and Prevention's Emerging Infections Program conducts active surveillance for persons hospitalized with laboratory-confirmed influenza in 59 counties in 10 states. We analyzed data for hospitalized adults during the 2007-2008 influenza season to evaluate the association between receiving statins and influenza-related death.
  
  
  RESULTS
  We identified 3043 patients hospitalized with laboratory-confirmed influenza, of whom 1013 (33.3%) received statins and 151 (5.0%) died within 30 days of their influenza test. Patients who received statins were more likely to be older, male, and white; to suffer from cardiovascular, metabolic, renal, and chronic lung disease; and to have been vaccinated against influenza that season. In a multivariable logistic regression model, administration of statins prior to or during hospitalization was associated with a protective odds of death (adjusted odds ratio, 0.59 [95% confidence interval, .38-.92]) when adjusting for age; race; cardiovascular, lung, and renal disease; influenza vaccination; and antiviral administration.
  
  
  CONCLUSIONS
  Statin use may be associated with reduced mortality in patients hospitalized with influenza.
authors.affiliation: Oregon Public Health Division, Portland, OR 97212, USA.
authors.forename: Meredith L
authors.initials: ML
authors.lastname: Vandermeer
authors.forename: Ann R
authors.initials: AR
authors.lastname: Thomas
authors.forename: Laurie
authors.initials: L
authors.lastname: Kamimoto
authors.forename: Arthur
authors.initials: A
authors.lastname: Reingold
authors.forename: Ken
authors.initials: K
authors.lastname: Gershman
authors.forename: James
authors.initials: J
authors.lastname: Meek
authors.forename: Monica M
authors.initials: MM
authors.lastname: Farley
authors.forename: Patricia
authors.initials: P
authors.lastname: Ryan
authors.forename: Ruth
authors.initials: R
authors.lastname: Lynfield
authors.forename: Joan
authors.initials: J
authors.lastname: Baumbach
authors.forename: William
authors.initials: W
authors.lastname: Schaffner
authors.forename: Nancy
authors.initials: N
authors.lastname: Bennett
authors.forename: Shelley
authors.initials: S
authors.lastname: Zansky
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D017052:Hospital Mortality; D006760:Hospitalization; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007251:Influenza, Human / Q000188:drug therapy / Q000401:mortality*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011159:Population Surveillance; D014481:United States / Q000453:epidemiology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors